AI Summary
This article discusses a study on a novel bispecific antibody-drug conjugate (BsADC) targeting PD-L1 and B7-H3 in laryngeal squamous cell carcinoma. The BsADC demonstrated enhanced antitumor efficacy compared to other ADC counterparts, with increased tumor cytotoxicity and activation of tumor-specific immunity. The BsADC showed promise in promoting immunogenic cell death and overcoming resistance to cancer treatments.
Background
Antibody-drug conjugates (ADCs) offer a promising approach, combining monoclonal antibodies with chemotherapeutic drugs to target cancer cells effectively while minimizing toxicity.
Methods
This study examined the therapeutic efficacy and potential mechanisms of a bispecific ADC (BsADC) in laryngeal squamous cell carcinoma. This BsADC selectively targets the immune checkpoints programmed cell death ligand-1 (PD-L1) and B7-H3, and the precise delivery of the small-molecule toxin monomethyl auristatin E.
Results
Our findings demonstrated that the BsADC outperformed its bispecific antibody and PD-L1 or B7-H3 ADC counterparts, particularly in terms of in vitro/in vivo tumor cytotoxicity, demonstrating remarkable immune cytotoxicity. Additionally, we observed potent activation of tumor-specific immunity and significant induction of markers of immunogenic cell death (ICD) and potential endoplasmic reticulum stress.
Conclusion
In conclusion, this novel BsADC, through immune checkpoint inhibition and promotion of ICD, amplified durable tumor immune cytotoxicity, providing novel insights and potential avenues for future cancer treatments and overcoming resistance.